Streetbeat News

Products Services

HHH

Howard Hughes Holdings has announced the launch of Teravalis, a new 37,000-acre community development in the Phoenix West Valley. This significant expansion marks a major step in the company's growth strategy, potentially impacting its market position and investor interest.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:21 am

LENZ

Lenz Therapeutics' shares surged following the success of its Phase 3 CLARITY study, where LNZ100 and LNZ101 treatments for presbyopia met the primary endpoint.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:20 am

VFF

Village Farms International has announced the commencement of operations at its new Renewable Natural Gas (RNG) facility, marking a significant step towards sustainability and diversification of its energy sources.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:11 am

AAPL

Apple Inc. has released the first beta version of iOS 17.5, allowing users in the European Union to download apps directly from developer websites, in compliance with the EU's Digital Markets Act. This update follows Apple's previous adaptations to the EU's app distribution regulations, including app sideloading and direct web downloads under specific conditions. Developers eligible for this feature must meet certain criteria and will be charged a €0.50 Core Technology Fee per download, bypassing Apple's commission.

Portfolio Pulse from Rounak Jain

April 03, 2024 | 11:11 am

AMZN

Amazon.com Inc.'s 'Just Walk Out' technology, initially marketed as AI-powered, was actually reliant on 1,000 contractors in India for operation. Despite its innovative approach to cashier-less shopping, the technology required human intervention in 7 out of 10 sales, leading Amazon to shift focus towards 'Dash Carts' and traditional self-checkout systems in its Amazon Fresh stores. This pivot reflects the challenges and higher costs associated with the 'Just Walk Out' system.

Portfolio Pulse from Rounak Jain

April 03, 2024 | 11:10 am

BABA

CGRO

PGJ

Alibaba Group Holding Ltd (NYSE:BABA) has significantly increased its share buy-back program, purchasing $4.8 billion in shares last quarter, marking its largest buy-back effort since 2021. The company also announced a collaboration with Space Epoch to deliver packages globally within an hour using a reusable rocket, XZY-1. This ambitious project aims to enhance Alibaba's logistics capabilities. Additionally, Alibaba's logistics arm, Cainiao, is expanding its 'five-day delivery' service internationally and boosting employee bonuses. Despite these efforts, BABA shares were down 0.95% in premarket trading. Investors can also gain exposure to Alibaba through Invesco Golden Dragon China ETF (NASDAQ:PGJ) and Tidal Trust II CoreValues Alpha Greater China Growth ETF (NYSE:CGRO).

Portfolio Pulse from Anusuya Lahiri

April 03, 2024 | 11:08 am

HSDT

Helius Medical Technologies, Inc. (NASDAQ:HSDT) has announced a partnership with Lovell Government Services to make its PoNS device, a therapeutic neuromodulation approach for balance and gait deficits, available to federal healthcare systems. The PoNS device is indicated for short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used alongside physical therapy.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:08 am

KTRA

Kintara Therapeutics (KTRA) and TuHURA Biosciences have agreed to merge in an all-stock transaction. TuHURA plans to advance a Phase 3 trial for its IFx-2.0 personalized cancer vaccine with Keytruda for advanced Merkel cell carcinoma in 2H 2024, aiming for FDA's accelerated approval. The merger includes a $31 million financing for TuHURA, expected to extend its cash runway into late 2025. TuHURA's bifunctional Antibody Drug Conjugates (ADCs) also present potential partnering opportunities.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:07 am

LENZ

Lenz Therapeutics announced positive Phase 3 CLARITY study results for two formulations of Aceclidine, LNZ100 and LNZ101, for Presbyopia. LNZ100, now the lead candidate, showed 71% of participants achieving significant vision improvement at 3 hours, with effects starting at 30 minutes and lasting up to 10 hours. A New Drug Application submission is anticipated in mid-2024.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:07 am

VNDA

Vanda Pharmaceuticals' Fanapt received FDA approval for the acute treatment of bipolar I disorder, leading to a rise in VNDA shares.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 11:05 am